Jeyanthi Ramanarayanan

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
New strategies have evolved in the treatment of patients with non-Hodgkin's lymphoma (NHL). Anti-sense oligonucleotides (ASO) and monoclonal antibody (mAb) therapy, though proven to be safe and(More)
Recent improved treatments for lymphoid malignancies produce more long-term survivors, yet increase the risk for secondary malignancies. Therapy-related myelodysplasia and acute myeloid leukemia are(More)
Imatinib, a selective ABL kinase inhibitor has improved therapeutic outcome in patients with Philadelphia positive chronic or acute leukemia. In the present study, we describe a 56-year-old male with(More)
8583 Antibody dependent cellular citotoxicity (ADCC) play a significant role in rituximab's anti-tumor activity. FcγRIIIa polymorphisms have been associated with clinical responses to rituximab. The(More)
3180 Background: Bcl-2 overexpression is associated with chemoresistance and poor outcome in large cell lymphoma. Recently, we demonstrated that rituximab- resistance is associated with upregulation(More)
  • 1